Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BIO 
Bio-Rad Laboratories Inc (BIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $326.5
1 Year Target Price $326.5
| 2 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.55% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.77B USD | Price to earnings Ratio 26.46 | 1Y Target Price 326.5 |
Price to earnings Ratio 26.46 | 1Y Target Price 326.5 | ||
Volume (30-day avg) 6 | Beta 0.91 | 52 Weeks Range 211.43 - 387.99 | Updated Date 08/28/2025 |
52 Weeks Range 211.43 - 387.99 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 11.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate 1.76 | Actual 2.61 |
Profitability
Profit Margin 12.5% | Operating Margin (TTM) 12.19% |
Management Effectiveness
Return on Assets (TTM) 1.59% | Return on Equity (TTM) 4.59% |
Valuation
Trailing PE 26.46 | Forward PE 35.34 | Enterprise Value 7798020722 | Price to Sales(TTM) 3.04 |
Enterprise Value 7798020722 | Price to Sales(TTM) 3.04 | ||
Enterprise Value to Revenue 2.27 | Enterprise Value to EBITDA 11.89 | Shares Outstanding 21992300 | Shares Floating 18506955 |
Shares Outstanding 21992300 | Shares Floating 18506955 | ||
Percent Insiders 16.19 | Percent Institutions 89.32 |
Upturn AI SWOT
Bio-Rad Laboratories Inc
Company Overview
History and Background
Bio-Rad Laboratories, Inc. was founded in 1952 in Berkeley, California. Initially focused on supplying research chemicals and equipment, it evolved into a global leader in life science research and clinical diagnostics.
Core Business Areas
- Life Science Group: Develops, manufactures, and markets a broad range of instruments, reagents, and consumables used by researchers to study genes, proteins, cells, and tissues. Products support genomics, proteomics, cell biology, and biopharma research.
- Clinical Diagnostics Group: Develops, manufactures, and markets in vitro diagnostics for clinical laboratories worldwide. Product lines include quality controls, immunoassay, molecular diagnostics, and blood typing.
Leadership and Structure
Norman Schwartz serves as Chairman and CEO. The company has a typical corporate structure with executive leadership overseeing the Life Science and Clinical Diagnostics groups, along with supporting functions like finance, marketing, and operations.
Top Products and Market Share
Key Offerings
- Droplet Digital PCR (ddPCR): A precision technology for nucleic acid quantification. Used in research and clinical diagnostics. Competitors include Thermo Fisher Scientific and QIAGEN. Revenue is significant, but specific figures are proprietary. Market Share is approximately 30-35%.
- Quality Controls: A comprehensive range of quality control products used in clinical laboratories to ensure accurate and reliable testing. Competitors include Roche Diagnostics and Abbott Laboratories. Revenue is substantial but specific data is proprietary. Market Share is estimated at 20-25%.
- Antibodies and Reagents: A vast portfolio of antibodies and reagents for a wide range of life science applications, which contributes to revenue for this segment but specific numbers are not availale. Main competitors include Thermo Fisher Scientific, Merck, and Cell Signaling Technology.
Market Dynamics
Industry Overview
The life science and clinical diagnostics industries are characterized by technological innovation, increasing regulatory requirements, and growing demand for personalized medicine.
Positioning
Bio-Rad holds a strong position due to its diversified product portfolio, strong brand reputation, and focus on innovation. The company competes based on product performance, breadth of offerings, and customer service.
Total Addressable Market (TAM)
The combined TAM for life science research and clinical diagnostics is estimated at hundreds of billions of dollars. Bio-Rad's position allows it to address a significant portion of this market, particularly in specialized segments like ddPCR and quality controls.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Diversified product portfolio
- Technological innovation
- Global presence
- Strong customer relationships
Weaknesses
- Exposure to economic cycles
- Competition from larger players
- Dependence on research funding levels
- Complexity of product development
Opportunities
- Growth in emerging markets
- Expansion of personalized medicine
- Development of new diagnostic technologies
- Acquisitions of complementary businesses
Threats
- Increased competition
- Pricing pressure
- Regulatory changes
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Roche Holding AG (RHHBY)
Competitive Landscape
Bio-Rad competes with larger, more diversified companies like Thermo Fisher and Danaher. Its strengths lie in its focused product portfolio and strong customer relationships.
Major Acquisitions
Exact Diagnostics
- Year: 2018
- Acquisition Price (USD millions): 145
- Strategic Rationale: Expanded Bio-Rad's quality control product line in the clinical diagnostics market.
Growth Trajectory and Initiatives
Historical Growth: Bio-Rad's growth has been driven by organic product development, acquisitions, and expansion into new markets.
Future Projections: Future growth projections depend on analyst estimates which are not included here but generally expect continued growth in core markets and new product areas.
Recent Initiatives: Recent initiatives include investments in new product development, strategic acquisitions, and expansion of the company's global presence.
Summary
Bio-Rad is a solid company with a strong position in the life science and clinical diagnostics markets. Its diversified product portfolio and brand reputation are working well. However, it faces strong competition and economic headwinds and needs to continue to innovate and expand into new markets to maintain its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly. Financial data is estimated and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bio-Rad Laboratories Inc
Exchange NYSE | Headquaters Hercules, CA, United States | ||
IPO Launch date 1966-01-01 | Chairman & CEO Mr. Norman D. Schwartz | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7700 | Website https://www.bio-rad.com |
Full time employees 7700 | Website https://www.bio-rad.com | ||
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.